IGF‑1 LR3 is a long‑acting IGF‑1 analogue that users take off‑label for muscle growth, hyperplasia, recovery and body‑recomposition. The community most often runs about 50 µg per day, with doses reported anywhere from 20 µg up to 10 mg, typically administered daily; cycling schedules are not standardized. The only clear limitation is that it has no FDA‑approved indication, so all human use is off‑label or compounded, and injection‑site reactions, edema, nausea and other common complaints have not emerged as consistent reports.
Data last updated
Measured on 4 of 6 axes
Evidence shape
The only published data for IGF‑1 LR3 come from animal‑only, preclinical mechanistic studies, so human evidence is absent. That single line of inquiry represents the entire research breadth, with no blinded or completed human trials to speak of. The lack of any registered or finished clinical work means there’s currently no human data to support any therapeutic use.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 27 out-of-stock offers not shown
How IGF-1 LR3 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community reports use IGF‑1 LR3 daily, typically around 100 µg (reported range 30 µg–10 mg), while a smaller group dose three times per week at about 1 mg (1–3 mg) or weekly at 500 µg; no cycling is described.